Journals / Türk Oftalmoloji Dergisi / 2008 / Cilt: 38 - Sayı: 1

Outcome of our intravitreal triamcinolone acetonide applications

İntravitreal triamsinolon asetonid uygulama sonuçlarımız

Pages
48–54
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was not any significant IOP change starting from the 1st month till the 6th month after the injection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To evaluate the outcome of our 4 mg intravitreal triamcinolone acetonide (IVTA) injections.METHOD: We evaluated the best corrected visual acuity (LogMAR), fundus fluorescein angiography (FFA) and intraocular pressure (IOP) before and 1st, 3rd, 6th months after IVTA injection in 97 eyes of 87 patients consisted from diabetic macular edema (47 eyes), central retinal (CRV) (17) and branched retinal vein occlusion (BRVO) (7) and age-related macular degeneration (ARMD) (26) patients, retrospectively.
📊
Key Findings & Data:RESULTS: Mean visual acuity before and 1st, 3rd, 6th months after injections were 0.87±0.58, 0.82±0.55, 0.73±0.49, 0.72±0.46 in diabetic macular edema group; 1.35±0.35, 1.22±0.45, 1.18±0.47, 1.17±0.49 in CRVO group; 1.12± 0.49, 0.94±0.54, 0.90±0.57, 0.85±0.61 in BRVO group; 1.25±0.45, 1.33±0.37, 1.20±0.53, 1.31±0.42 in ARMD group, respectively.
💡
Conclusion & Impact:There was not any significant IOP change starting from the 1st month till the 6th month after the injection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PURPOSE: To evaluate the outcome of our 4 mg intravitreal triamcinolone acetonide (IVTA) injections.METHOD: We evaluated the best corrected visual acuity (LogMAR), fundus fluorescein angiography (FFA) and intraocular pressure (IOP) before and 1st, 3rd, 6th months after IVTA injection in 97 eyes of 87 patients consisted from diabetic macular edema (47 eyes), central retinal (CRV) (17) and branched retinal vein occlusion (BRVO) (7) and age-related macular degeneration (ARMD) (26) patients, retrospectively. RESULTS: Mean visual acuity before and 1st, 3rd, 6th months after injections were 0.87±0.58, 0.82±0.55, 0.73±0.49, 0.72±0.46 in diabetic macular edema group; 1.35±0.35, 1.22±0.45, 1.18±0.47, 1.17±0.49 in CRVO group; 1.12± 0.49, 0.94±0.54, 0.90±0.57, 0.85±0.61 in BRVO group; 1.25±0.45, 1.33±0.37, 1.20±0.53, 1.31±0.42 in ARMD group, respectively. The only statistical significant increasement in visual acuity was detected in the 3rd (*p: 0.003, *p: 0.044) and 6th month (*p: 0.002, *p: 0.046) in the diabetic macula edema and CRVO groups. The visual acuity alterations in other groups and IOP alterations in all groups did not show any significant difference from the baseline (p>0.05).In FFA at the 6th month, in diabetic macular edema group and CRVO group macular edema markedly decreased in 15 eyes (%32) and 10 eyes (%59), minimally decreased in 25 eyes (%53) and 7 eyes (%41), respectively. In BRVO group in 7 eyes (%100) decreased minimally. In ARMD patients there was not any documented leakage.CONCLUSION: IVTA injection resulted statistical significant increasement in the visual acuity in macular edema secondary to diabetes mellitus and CRVO. There was not any significant IOP change starting from the 1st month till the 6th month after the injection.

Özet

AMAÇ: İntravitreal triamsinolon asetonid (İVTA) uygulama sonuçlarımızın değerlendirilmesi. YÖNTEM: 02.01.06–02.01.07 tarihleri arasında, 4 mg İVTA enjeksiyonu uygulanan ve 1. 3. ve 6. ay takipleri yapılan diyabete (47 göz), santral retinal ven (SRV) (17) ve retinal ven dalcık (7) oklüzyonuna (RVDO) sekonder makula ödemi (MÖ) ve yaşa bağlı makula dejenerasyonlu (YBMD) (26 göz) toplam 97 gözün (87 hasta), görme, FFA ve göz içi basınç (GİB) bulgularının retrospektif incelenmesi. BULGULAR: Görme keskinlik (LogMAR) ortalamaları: diyabetik MÖ grubun’da İVTA öncesi 0.87±0.58, sonrası 1. ay 0.82±0.55, 3. ay 0.73±0.49, 6. ay 0.72±0.46; SRVO grubunda sırasıyla 1.35±0.35, 1.22±0.45, 1.18±0.47, 1.17±0.49; RVDO grubunda 1.12± 0.49, 0.94±0.54, 0.90±0.57, 0.85±0.61; YBMD grubunda 1.25±0.45, 1.33±0.37, 1.20±0.53, 1.31±0.42 idi. İstatistiksel anlamlı artış, sadece diyabetik MÖ ve SRVO grubunda 3. (*p: 0.003, *p: 0.044) ve 6. (*p: 0.002, *p: 0.046) aylarda tespit edildi. Diğer gruplardaki görme ve tüm gruplardaki GİB değişimleri istatistiksel anlamlı değildi (p>0.05). FFA’de 6. ayda diyabetik MÖ grubunda gözlerin 15’inde (%32) MÖ’de belirgin, 25’inde (%53) minimal, SRVO grubunda gözlerin 10’unda (%59) belirgin, 7’sinde (%41) minimal, RVDO grubunda 7 gözün tümünde (%100) minimal azalma izlendi. YBMD grubundaki hiçbir hastada sızıntı kalmamıştı. SONUÇ: İVTA enjeksiyonu diyabete ve SRV oklüzyonuna sekonder MÖ’de istatiksel anlamlı görme artışını sağlayabilmektedir. İVTA enjeksiyonu 1. aydan itibaren 6 aylık takip süresince istatiksel anlamlı GİB değişimi yapmamaktadır

🔖

Cite This Article

AYDEMİR, O., TURGUT, B., TÜRKÇÜOĞLU, P., ARSLAN, S., ÇELİKLER, Ü. (2022). Outcome of our intravitreal triamcinolone acetonide applications. Türk Oftalmoloji Dergisi, Cilt: 38 - Sayı: 1, 48–54. https://ajindex.com/articles/638574

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabeticmacular ede ma. Am J Ophthalmol 2001; 132:425-427
  2. Park CH, Jaffe GJ, Fekrat S. intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136:419-425
  3. Ozkiris A, Evereklioglu C, Erkilic K ve ark. The efficacy of intravitreal triamcinolone acetonide on macular edema in branch retinal vein occlusion. Eur J Ophthalmol. 2005;15:96-101
  4. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamci nolone acetonide in exudative age-related macular dege neration.Retina 2000;20:244-250
  5. Vinores S A, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non ischemic human and experimental retinal disease. Histol Histopathol 1997; 12:99-109
  6. Aiello LP, Bursell SE, Clermont A, et al. Vascular endot helial growth factor-induced retinal permeability is medi ated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480
  7. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth-factor is downregulated by corti costeroids. Am J Respir Cell Mol Biol 1997; 16:398-406
  8. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corti costeroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315
  9. Baath J, Ells AL, Crichton A, et al. Safety profile of intra vitreal triamcinolone acetonide. J Ocul Pharmacol Ther. 2007;23:304-310
  10. Sivaprasad S, McCluskey P and Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol. Scand 2006;84:722-733
  11. Tano Y, Chandler D, Machemer R. Treatment of intrao cular proliferation with intravitreal injection of triamcino lone acetonide. Am J Ophthalmol 1980;90:810-816
  12. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of pre retinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104
  13. Chin HS, Park TS, Moon YS, et al. Difference in clearan ce of intravitreal triamcinolone acetonide between vitrec tomized and nonvitrectomized eyes. Retina. 2005;25:556-560
  14. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J O